NATCO Pharma Limited

NSE:NATCOPHARM.NS

1577.75 (INR) • At close September 16, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

20232022202120202019201820172016201520142013201220112010200920082007200620052004
Revenue 39,98827,07119,04916,90318,87820,61821,56720,39911,248.4718,186.3337,307.5876,500.585,200.4644,373.8394,307.5314,381.9853,277.3732,415.2321,680.9131,544.032
Cost of Revenue 14,2846,2736,8156,0795,1004,6195,0896,9403,931.2942,832.4772,757.8632,756.0562,377.598789.265813.278967.464898.329856.1251,325.4231,155.789
Gross Profit 25,70420,79812,23410,82413,77815,99916,47813,4597,317.1775,353.8564,549.7233,744.5242,822.8653,584.5753,494.2533,414.5222,379.0431,559.108355.49388.243
Gross Profit Ratio 0.6430.7680.6420.640.730.7760.7640.660.6510.6540.6230.5760.5430.820.8110.7790.7260.6460.2110.251
Reseach & Development Expenses 1,2119021,7691,473633724462460150.702126.085142.852146.33684.271110.46277.88600000
General & Administrative Expenses 01,069818565587514381380252.228241.465266.438133.627506.698397.774261.421525.425413.847330.72500
Selling & Marketing Expenses 09614373449811,3721,3691,4321,126.775373.582261.604148.207225.275132.42125.58155.88743.19832.86100
SG&A 10,0582,0301,2559091,5681,8861,7501,8121,379.002615.047528.042281.834731.973530.194387.001581.312457.045363.58600
Other Expenses 1,2811,046401104020161118.1514.19214.1453.9965.0062,050.803-3.42-35.766-11.049-18.094116.57671.293
Operating Expenses 10,05813,08010,8105,8148,8668,8197,7236,9044,954.3023,646.1643,043.8652,425.3291,885.3082,691.4582,636.1862,653.5711,715.0171,055.84116.57671.293
Operating Income 15,6468,7642,1995,0104,9127,1808,7556,5552,362.8761,707.6921,505.8581,319.195937.557893.116858.067760.951664.026503.267238.913316.95
Operating Income Ratio 0.3910.3240.1150.2960.260.3480.4060.3210.210.2090.2060.2030.180.2040.1990.1740.2030.2080.1420.205
Total Other Income Expenses Net 1,089-145-1777867751,067117-311-296.637-365.52-216.09-296.002-142.139-241.884-226.51-194.543-110.851-105.35433.254-309.453
Income Before Tax 16,7358,6192,0225,7965,6878,2478,8726,2442,066.2381,342.1721,289.7681,023.193795.418651.232631.557566.408553.175397.913272.1677.497
Income Before Tax Ratio 0.4190.3180.1060.3430.3010.40.4110.3060.1840.1640.1760.1570.1530.1490.1470.1290.1690.1650.1620.005
Income Tax Expense 2,8521,4663221,3721,1061,8231,9201,395527.97839.502308.7364.364210.748132.113136.612112.896148.03893.28734.233-8.071
Net Income 13,8837,1531,7004,4094,6086,4446,9624,8601,551.7541,346.1581,027.343718.691596.083535.111487.181439.719405.137304.626237.93415.568
Net Income Ratio 0.3470.2640.0890.2610.2440.3130.3230.2380.1380.1640.1410.1110.1150.1220.1130.10.1240.1260.1420.01
EPS 77.3439.189.3224.225.3334.9839.2627.899.148.136.434.64.113.83.463.142.892.21.750.12
EPS Diluted 77.3439.189.3224.1625.2634.8739.1327.879.118.136.434.584.113.83.463.142.892.21.750.12
EBITDA 17,51410,4023,3406,8506,7549,1049,6967,2112,885.4252,245.9011,937.0071,606.3831,126.5171,151.8371,145.735922.352768.748611.55433.259425.575
EBITDA Ratio 0.4380.3840.1750.4050.3580.4420.450.3530.2570.2740.2650.2470.2170.2630.2660.210.2350.2530.2580.276